#USA #Milford #Waters Corporation #Halo Labs #Biopharmaceutical Analysis

Waters Corporation Expands Its Portfolio with Halo Labs Acquisition

In a significant strategic move, Waters Corporation (NYSE: WAT) announced on May 21, 2025, that it has acquired Halo Labs™, a cutting-edge company specializing in imaging technologies designed to detect, identify, and quantify interfering materials in therapeutic products. This acquisition is expected to enhance Waters' capabilities in the field of biological analysis, particularly in the development and quality assurance of large molecule therapies such as cell, protein, and gene therapies.

The acquisition emphasizes Waters' commitment to integrating advanced technologies into its solutions. Winner of the prestigious Wyatt Technology™ portfolio, Halo Labs brings to the table its innovative Aura™ platform, which utilizes full-spectrum particle analysis. This technology stands out by providing insights into subvisible particles that can interfere in therapeutic processes, particularly in the context of CAR T-cell therapies. By identifying these hidden process impurities, Waters aims to ensure higher standards of quality in drug manufacture, which is crucial in today's fast-evolving biopharmaceutical landscape.

Dr. Udit Batra, President and CEO of Waters Corporation, highlighted the importance of this acquisition by stating, "The addition of Halo Labs' low-sample-volume, high-throughput technology equips us with advanced analysis tools for various sample types and volumes. This integration will offer earlier insights during therapy development, ensuring greater safety during manufacturing stages. With the rapid advancements in treatments like CAR T-cells, our strategic investment is aligned with the needs of our customers and the industry."

Moreover, Rick Gordon, CEO of Halo Labs, expressed his enthusiasm about joining forces with Waters, stating that both companies share a vision of purposeful innovation and a focus on customer needs. Gordon emphasized the potential for their combined technologies to drive improvements in therapeutic development and production while upholding their commitment to drug quality and safety. This collaboration is seen as a mutually beneficial partnership, accelerating the reach of Halo Labs' platform and expanding its market presence.

The financial implications of this acquisition are projected to be minimal on Waters’ income statement over the next 12 months, allowing the company to make a bold move without significant immediate fiscal pressure. However, the long-term benefits are anticipated to significantly enhance Waters' standing in analytical technologies for the biopharma sector.

With over 65 years of leadership in analytical instruments and separations technologies, Waters Corporation continues to serve vital sectors, including life sciences, materials analysis, food safety, and environmental sciences. This acquisition marks another chapter in Waters’ ongoing journey to advance the efficacy and safety of medicines.

As Halo Labs focuses on providing high-throughput biopharmaceutical formulation, stability, and quality control tools, Waters Corporation will undoubtedly leverage these advanced insights to help biopharmaceutical companies enhance the safety and effectiveness of their drug products. The collaborative innovations that will stem from this acquisition will likely lead to groundbreaking advancements that can benefit patients worldwide.

Through this strategic acquisition, Waters Corporation not only strengthens its position in the bioprocessing landscape but also demonstrates its commitment to meeting the growing demands of the biopharmaceutical market, paving the way for future innovations that prioritize patient safety and drug quality. Stakeholders can look forward to significant developments as this partnership unfolds, bridging the gap between innovative science and therapeutic efficacy.